Q4 2025 · 13F-HR
EcoR1 Capital, LLCholdings as filed
Filed 2026-02-17 · accession 0000935836-26-000101
$2.20B
Reported value
30
Positions
2025-12-31
Period end
The Brief · EcoR1 Capital, LLC · Q4 2025
AI · grounded in 13F
EcoR1 Capital, LLC closed its position in QURE, reducing exposure by $232.8M. The fund also exited positions in TNGX and APLSUSD, totaling $89.3M and $78M respectively. On the buy side, the fund established a new position in CGON for $44.2M and increased its stake in CNTA by 466.4%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 98985Y108 | ZYME | ZYMEWORKS INC | $604.8M | 27.4% | 22,970,388 | Common | SOLE |
| 032724106 | ANAB | ANAPTYSBIO INC | $382.0M | 17.3% | 7,880,094 | Common | SOLE |
| G50871105 | JAZZ | JAZZ PHARMACEUTICALS PLC | $290.1M | 13.2% | 1,706,469 | Common | SOLE |
| 22663K107 | CRNX | CRINETICS PHARMACEUTICALS IN | $199.6M | 9.06% | 4,288,120 | Common | SOLE |
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS PLC | $77.9M | 3.53% | 3,115,000 | Common | SOLE |
| H17182108 | CRSP | CRISPR THERAPEUTICS AG | $72.9M | 3.31% | 1,389,276 | Common | SOLE |
| 55287L101 | MBX | MBX BIOSCIENCES INC | $67.0M | 3.04% | 2,123,604 | Common | SOLE |
| 45257U108 | IMNM | IMMUNOME INC | $61.3M | 2.78% | 2,855,590 | Common | SOLE |
| 68622P109 | ORIC | ORIC PHARMACEUTICALS INC | $55.0M | 2.50% | 6,728,116 | Common | SOLE |
| 36315X101 | LKFT | GALAPAGOS NV | $54.5M | 2.47% | 1,667,119 | Common | SOLE |
| 98401F105 | XNCR | XENCOR INC | $49.8M | 2.26% | 3,251,112 | Common | SOLE |
| 107924102 | BBOT | BRIDGEBIO ONCOLOGY THERAPEUT | $35.3M | 1.60% | 2,823,126 | Common | SOLE |
| 29772L108 | ETON | ETON PHARMACEUTICALS INC | $34.3M | 1.56% | 2,030,544 | Common | SOLE |
| 156944100 | CGON | CG ONCOLOGY INC | $32.1M | 1.45% | 772,000 | Common | SOLE |
| 98937L105 | ZBIO | ZENAS BIOPHARMA INC | $28.7M | 1.30% | 789,500 | Common | SOLE |
| 64135M105 | NGNE | NEUROGENE INC | $26.2M | 1.19% | 1,271,342 | Common | SOLE |
| 86366E106 | GPCR | STRUCTURE THERAPEUTICS INC | $23.3M | 1.06% | 334,380 | Common | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $20.8M | 0.94% | 450,000 | Common | SOLE |
| 03843E104 | AQST | AQUESTIVE THERAPEUTICS INC | $17.0M | 0.77% | 2,625,000 | Common | SOLE |
| 92915B106 | VYGR | VOYAGER THERAPEUTICS INC | $15.7M | 0.71% | 4,002,847 | Common | SOLE |
| 156944100 | CGON | CG ONCOLOGY INC | $12.2M | 0.55% | 292,800 | CALL | SOLE |
| 046513206 | ATRA | ATARA BIOTHERAPEUTICS INC | $10.4M | 0.47% | 573,183 | Common | SOLE |
| 56400P706 | MNKD | MANNKIND CORP | $9.4M | 0.43% | 1,660,000 | Common | SOLE |
| 67080N119 | NUVB/WS | NUVATION BIO INC | $8.6M | 0.39% | 963,333 | Common | SOLE |
| 30052C107 | EOLS | EVOLUS INC | $4.5M | 0.20% | 675,000 | Common | SOLE |
| 451033708 | IBIO | IBIO INC | $4.3M | 0.20% | 2,228,000 | Common | SOLE |
| 589492107 | MREO | MEREO BIOPHARMA GROUP PLC | $3.3M | 0.15% | 7,856,466 | Common | SOLE |
| 13463J101 | CAMP | CAMP4 THERAPEUTICS CORP | $2.0M | 0.09% | 325,000 | Common | SOLE |
| 98401F105 | XNCR | XENCOR INC | $1.0M | 0.05% | 67,500 | CALL | SOLE |
| 86889P117 | SRZNW | SURROZEN INC | $100,434 | 0.00% | 4,444 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.